J B Chemicals Share Tips, Live Price, News & Info

J B Chemicals & Pharmaceuticals (JBC), flagship company of the Unique group, manufactures basic chemicals, petrochemicals, pharmaceuticals, photographic chemicals and agro-based products. Its product portfolio includes metrogyl, rantac (a ranitidine-based formulation), and nicardia (a cardiac care medicine). The company has 11 manufacturing facilities across four locations. Its APIs include (metronidazole and its intermediates, diclofenac sodium, potassium and other salts of diclofenac and nifedipine), tablets, injectables (SVP and LVP), liquid suspensions, syrups and ointments markets. It has a fully automated 100 per cent EOU lozenges plant (capacity 400 mn units p.a.) at Daman, manufacturing hard catidies. The company plans to increase therapeutic presence in the high growth chronic care segment. Accordingly, it has launched its CMS division and entered into new therapeutic groups such as anti-diabetics, nutritional and urology segments. It has invested Rs 650 million in a new facility at Panoli, India for manufacture of APIs and large/small volume parenterals. The company`s exports contribute 57 per cent to its revenues. JBC created a new SBU called Zephyr to service emerging needs in the neuro-psychiatric and urology segments. The USFDA has accepted the company`s US DMF for Ciprofloxacin Hydrochloride (API). Once approved, JBC will become the third company in India to have both ANDA and DMF approvals for ciprofloxacin. The company plans to continue its R & D efforts in major thrust areas, namely NDDS, natural products and APIs and to further its therapeutic categories of cardiac care, anti-infective, anti-ulcerants and NSAID. It also has plans for R&D including custom synthesis of specialty intermediates.